Article Sidebar

Published: 2026-08-14
Abstract Views: 0
DOI: https://doi.org/10.52163/yhc.v67iCD12.6132
Issue
Tập 67 Số CĐ12- HNKH Bệnh viện Ung bướu Nghệ An
Section
Articles
How to Cite
Hoàng, N. H., Công, N. V., Ngọc, T. T. Ánh, Thượng, N. T., & Nhung, P. T. (2026). KẾT QUẢ XẠ TRỊ KỸ THUẬT ĐIỀU BIẾN LIỀU KẾT HỢP ĐỒNG THỜI HOÁ TRỊ PHÁC ĐỒ PACLITAXEL – CARBOPLATIN BỆNH UNG THƯ THỰC QUẢN 1/3 TRÊN TẠI BỆNH VIỆN UNG BƯỚU NGHỆ AN. Vietnam Journal of Community Medicine, 67(CD12). https://doi.org/10.52163/yhc.v67iCD12.6132

KẾT QUẢ XẠ TRỊ KỸ THUẬT ĐIỀU BIẾN LIỀU KẾT HỢP ĐỒNG THỜI HOÁ TRỊ PHÁC ĐỒ PACLITAXEL – CARBOPLATIN BỆNH UNG THƯ THỰC QUẢN 1/3 TRÊN TẠI BỆNH VIỆN UNG BƯỚU NGHỆ AN

Nguyen Hai Hoang1, Nguyen Van Cong1, Tran Thi Anh Ngoc1, Nguyen Tien Thuong1, Pham Thi Nhung1
1 Nghe An Oncology Hospital.

Main Article Content

Abstract

Objective: To evaluate the outcomes of intensity-modulated radiotherapy (IMRT) combined with concurrent Paclitaxel - Carboplatin (PC) chemotherapy in patients with upper-third esophageal cancer (EC) at Nghe An Oncology Hospital.


Subjects and Methods: A retrospective and prospective descriptive study was conducted on 32 patients with stage II-IVa upper-third esophageal cancer treated with IMRT and Paclitaxel - Carboplatin chemotherapy from January 2022 to June 2026. Post-treatment response was evaluated based on the RECIST 1.1 criteria. Early toxicities and adverse effects were assessed using the CTCAE v5.0 criteria.


Results: Dysphagia symptoms improved in 78.1% of the patients. The treatment responses were as follows: complete response (CR) in 18.8%, partial response (PR) in 59.4%, stable disease (SD) in 12.5%, and progressive disease (PD) in 9.4%. There were statistically significant differences in response rates according to T stage, and overall disease stage (p < 0.05). Early adverse effects were predominantly Grade 1-2, including dermatitis (59.4%), esophagitis (84.4%), decreased hemoglobin (18.8%), and neutropenia (15.6%).


Conclusion: The IMRT technique combined with the Paclitaxel - Carboplatin regimen for patients with upper-third esophageal cancer demonstrates high clinical and subclinical responses, with low and manageable adverse effects.

Article Details

Keywords

Upper-third esophageal cancer; Intensity-modulated radiotherapy (IMRT); Concurrent chemoradiotherapy; Paclitaxel - Carboplatin; RECIST 1.1.

References

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 2.2025. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025.
2. Van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-2084. doi:10.1056/NEJMoa1112088. (CROSS trial)
3. Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090-1098.
4. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018;36(27):2796-2803. doi:10.1200/JCO.2018.79.1483.
5. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial. JAMA Surg. 2021;156(8):721-729.
6. RTOG 85-01 Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593-1598.
7. ARTDECO trial Hulshof MCCM, Geijsen ED, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, et al. Randomized study on dose escalation in definitive chemoradiation for esophageal cancer (ARTDECO). Lancet Oncol. 2021;22(7):919-927.